Table 1.
No LFT# |
LFT# |
p-value |
|
---|---|---|---|
(n = 58) | (n = 128) | ||
Age | 37 (29–50) | 39 (30–47) | 0·960 |
Gender | 0·390 | ||
Female | 18 (31%) | 32 (25%) | |
Male | 40 (69%) | 96 (75%) | |
Immunity | 0·270 | ||
Unknown | 3 (5%) | 1 (1%) | |
Non-immune | 27 (47%) | 57 (45%) | |
Partially | 26 (45%) | 65 (51%) | |
Semi | 2 (3%) | 5 (4%) | |
Parasitaemia/μL | 7·611 (1·582–44·550) | 5·466 (1·146–47·100 | 0·811 |
AST (U/L) | 21 (17–26) | 41 (31–63) | <0·001 |
ALT (U/L) | 25 (19–30) | 48 (34–68) | <0·001 |
γGT (U/L) | 30 (20–37) | 71 (49–113) | <0·001 |
Alkaline phosphatase (U/L) | 65 (57–79) | 83 (64–101) | <0·001 |
Bilirubin (total) (μmol/L) | 21 (10–28) | 22 (15–31) | 0·039 |
LD (U/L) | 275 (196–304) | 286 (113–346) | 0·181 |
Haemoglobin (mmol/L) | 8·1 (7·4–8·9) | 8·7 (7·7–9·4) | 0·006 |
Leukocytes (x109/L) | 4·9 (4·0–5·8) | 4·9 (3·6–6·4) | 0·863 |
Lymphocytes (x109/L) | 0·9 (0·6–1·4) | 0·9 (0·6–1·4) | 0·998 |
Thrombocytes (x109/L) | 125 (69–174) | 87 (56–131) | 0·008 |
CRP (mg/L) | 64 (30–116) | 106 (56–158) | 0·001 |
Creatinine (μmol/L) | 95 (81–108) | 95 (81–108) | 0·400 |
Urea (mmol/L) | 4·9 (3·9–6·2) | 5·2 (4·0–6·4) | 0·498 |
Sodium (mmol/L) | 136 (133–138) | 135 (133–138) | 0·578 |
Potassium (mmol/L) | 3·8 (3·5–4·2) | 3·7 (3·5–4·0) | 0·299 |
Lactate (mmol/L) | 1·3 (1·0–1·5) | 1·4 (1·1–1·9) | 0·017 |
Temperature (°C) | 37·6 (36·9–38·8) | 38·9 (37·5–39·5) | 0·001 |
Treatment | 0·532 | ||
atovaquone/proguanil | 50 (86%) | 108 (84%) | |
quinine | 4 (7%) | 4 (3%) | |
artemether/lumefantrine | 4 (7%) | 2 (2%) | |
artesunate | 13 (10%) | ||
chloroquine | 1 (1%) | ||
Severity LFT# | n/a | ||
Mild LFT# | n/a | 93 (73%) | |
Moderate LFT# | n/a | 26 (20%) | |
Severe LFT# | n/a | 9 (7%) |
All data are presented as median (IQR) or N (%). LFT# = liver function test abnormalities. Statistical differences are tested using Mann-Whitney or Chi square. Clinical laboratory reference ranges can be found in S2 table.